Skip to main content

Fletcher Aaron G.L.'s Form 4 filing

Cognition Therapeutics Inc (CGTX) · filed Oct 15, 2021

Accession no.
0001104659-21-126905
Filed
Oct 15, 2021, 9:51 PM ET
Trade date
Oct 13, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 18 non-derivative transactions and 14 derivative transactions. Open-market purchases total $2.28M. Open-market sales total $1.08K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fletcher Aaron G.L.CIK 0001789490Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 13, 2021Common StockCConversionAcquired+1,424,014–F1–1,424,014Indirect
Oct 13, 2021Common StockCConversionAcquired+418,926–F1–418,926Indirect
Oct 13, 2021Common StockCConversionAcquired+245,029–F1–245,029Indirect
Oct 13, 2021Common StockCConversionAcquired+78,298–F2–78,298Indirect
Oct 13, 2021Common StockCConversionAcquired+255,765–F2–255,765Indirect
Oct 13, 2021Common StockCConversionAcquired+34,238–F2–34,238Indirect
Oct 13, 2021Common StockPPurchaseAcquired+23,341$12.00+$280,09257,579Indirect
Oct 13, 2021Common StockCConversionAcquired+351,844–F2–351,844Indirect
Oct 13, 2021Common StockXIn-the-money exerciseAcquired+33,495$0.032+$1,071.84385,339Indirect
Oct 13, 2021Common StockSSaleDisposed−90.28$12.00−$1,083.36385,248Indirect
Oct 13, 2021Common StockCConversionAcquired+41,620–F2–41,620Indirect
Oct 13, 2021Common StockCConversionAcquired+24,263–F3,F5–65,883Indirect
Oct 13, 2021Common StockPPurchaseAcquired+22,129$12.00+$265,54888,012Indirect
Oct 13, 2021Common StockCConversionAcquired+596,899–F2–596,899Indirect
Oct 13, 2021Common StockCConversionAcquired+158,476–F5–755,375Indirect
Oct 13, 2021Common StockPPurchaseAcquired+144,530$12.00+$1,734,360899,905Indirect
Oct 13, 2021Common StockCConversionAcquired+34,472–F2–34,472Indirect
Oct 13, 2021Common StockCConversionAcquired+25,593–F5–60,065Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 13, 2021Common StockCConversionDisposed−1,424,014$0.00$00Direct
Oct 13, 2021Common StockCConversionDisposed−418,926$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−245,029$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−78,298$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−255,765$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−351,844$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−34,238$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−41,620$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−596,899$0.00$00Indirect
Oct 13, 2021Common StockCConversionDisposed−34,472$0.00$00Indirect
Oct 13, 2021Common StockXIn-the-money exerciseDisposed−33,495$0.00$00Indirect
Oct 13, 2021Simple Agreement for Future EquityCConversionDisposed−24,263$0.00$00Indirect
Oct 13, 2021Simple Agreement for Future EquityCConversionDisposed−158,476$0.00$00Indirect
Oct 13, 2021Simple Agreement for Future EquityCConversionDisposed−25,593$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The Series B Convertible Preferred Stock converted into Cognition Therapeutics, Inc. ("CGTX") common stock upon the closing of the issuer's initial public offering ("IPO"), as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.

Referenced by the price of 3 transactions in Table I.

F2

The Series B-1 Convertible Preferred Stock converted into CGTX common stock upon the closing of the issuer's IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.

Referenced by the price of 7 transactions in Table I.

F3

On October 13, 2021, the reporting person exercised a warrant to purchase 33,495 shares of CGTX common stock for $0.032 per share. The reporting person paid the exercise price on a cashless basis, resulting in CGTX's withholding of 90.28 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 33,404 shares. The issuer paid cash to the reporting person in lieu of any fractional share amounts.

Referenced by the price of 1 transaction in Table I.

F5

The Simple Agreement for Future Equity converted into CGTX common stock upon the closing of the issuer's IPO at 80% of the per share offering price of the IPO, as adjusted for a 1-for-3.2345 reverse stock split, and had no expiration.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)